PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1…